Vertex Gears Up For Next Generation In CF Therapy

Vertex Pharmaceuticals Inc.'s newest cystic fibrosis drug Orkambi (lumacaftor/ivacaftor) has exceeded Wall Street projections for prescriptions and patient starts, the company reported during its third quarter earnings call Oct. 28.